Search

Displaying results 4291 - 4300 of 8575 in total
  1. Drug

    PPL-100

    go.drugbank.com/drugs/DB05961
    Investigational

  2. Drug

    SCB-2019

    go.drugbank.com/drugs/DB15805
    Investigational

    The vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd.. … As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908) to test the safety and immunogenicity of the vaccine.

  3. Drug

    BMS-754807

    go.drugbank.com/drugs/DB15399
    Investigational

    BMS-754807 is under investigation in clinical trial NCT00908024 (Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors).

  4. Drug

    Acellular nerve allograft

    go.drugbank.com/drugs/DB30293
    ApprovedInvestigational

    Approved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral

  5. Drug

    Mercaptopurine

    go.drugbank.com/drugs/DB01033
    ApprovedInvestigational

    An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission...

  6. Drug

    Boldenone undecylenate

    go.drugbank.com/drugs/DB14639
    ExperimentalIllicitVet approved

  7. Drug

    ROX-888

    go.drugbank.com/drugs/DB05364
    Experimental

    ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.

  8. Drug

    Spaglumic acid

    go.drugbank.com/drugs/DB08835
    Investigational

    Thus it is used in allergic conditions such as allergic conjunctivitis.

  9. Drug

    TMC-310911

    go.drugbank.com/drugs/DB15623
    Investigational

    TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available [darunavir]. … [L12045,A191643] TMC-310911 is currently being investigated, in combination with other HIV therapies and antivirals, as a potential treatment for COVID-19 caused by SARS-CoV-2.[L12012]

  10. Drug

    CHF 4227

    go.drugbank.com/drugs/DB05882
    Experimental

    The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. … Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used in postmenopausal therapy.